FDA’s Final MOU On Interstate Compounding Now Awaits Signatures From States

A pharmacy compounding group said it believes the US Food and Drug Administration has overestimated the number of states that will sign its recently issued final memorandum of understanding (MOU) on interstate compounding, and that some states cannot implement the agreement because there do not have the funding nor the manpower to support the MOU’s reporting requirements.

Pharmacy groups say that what is at stake is lack of out-of-state patient access to medicines compounded in states that...